Liege, Belgium, 24 September 2021 - 7:45 CEST - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces topline results of the Coronesta Phase II study, which aimed to assess the safety and efficacy of estetrol (E4) for the treatment of patients who were hospitalized with moderate COVID-19. E4 is a native occurring estrogen produc

ed by the human fetus during pregnancy.

Attachments

  • Original document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 24 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 24 September 2021 06:01:02 UTC.